Literature DB >> 29121010

Allergan's Mohawk evergreening patent deal draws criticism, but ultimately may flop.

Eva von Schaper.   

Abstract

Mesh:

Substances:

Year:  2017        PMID: 29121010     DOI: 10.1038/nbt1117-1002

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  An update on obtaining and enforcing therapeutic antibody patent claims.

Authors:  Theresa Gresl; Ulrich Storz; Colin Sandercock
Journal:  Nat Biotechnol       Date:  2016-12-07       Impact factor: 54.908

2.  America's drug problem.

Authors:  Brady Huggett
Journal:  Nat Biotechnol       Date:  2016-11-14       Impact factor: 54.908

  2 in total
  1 in total

1.  Patent challenges to antibody and gene-therapy firms on the rise.

Authors:  Charlotte Harrison
Journal:  Nat Biotechnol       Date:  2018-05-09       Impact factor: 54.908

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.